Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making.

ABSTRACT:

Background

The current drug development paradigm has been criticized for being too drug-centered and for not adequately focusing on the patients who will eventually be administered the therapeutic interventions it generates. The drug-driven nature of the present framework has led to the emergence of a research gap between the pre-approval development of anticancer medicines and their post-registration use in real-life clinical practice. This gap could potentially be bridged by transitioning toward a patient-centered paradigm that places a strong emphasis on treatment optimization, which strives to optimize the way health technologies are applied in a real-world environment. However, questions remain concerning the ideal features of treatment optimization studies and their acceptabi

SUBMITTER: Saesen R 

PROVIDER: S-EPMC7015135 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature